Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kane BiotechKNBIF -15.53% EV-to-Revenue is 131.67 as of Aug. 29, 2026, which is 1293% above its 10-year median of 9.45. The stock has 6 warning signs investors should review. Among 958 Biotechnology companies, Kane Biotech ranks worse than 85.49% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Kane Biotech's enterprise value is $5.53 Mil.
Kane Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $0.04 Mil. Therefore, Kane Biotech's EV-to-Revenue for today is 131.67.
The historical rank and industry rank for Kane Biotech's EV-to-Revenue or its related term are showing as below:
KNBIF'
s EV-to-Revenue Range Over the Past 10 Years
Min: -68.38 Med: 9.45 Max: 167.25
Current: 132.31
During the past 13 years, the highest EV-to-Revenue of Kane Biotech was 167.25. The lowest was -68.38. And the median was 9.45.
KNBIF's EV-to-Revenue is ranked worse than 85.49% of 958
companies
in the Biotechnology industry
Industry Median: 8.715
vs KNBIF: 132.31
As of today (2026-08-29), Kane Biotech's stock price is $0.0185.
Kane Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Therefore, Kane Biotech's PS Ratio for today is .
Kane Biotech's share price for today is $0.0185.
Kane Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kane Biotech EV-to-Revenue Related Terms
Kane Biotech EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Kane Biotech's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNBIF vs VRTX, REGN, RVMD: EV-to-Revenue Comparison
For the Biotechnology subindustry, Kane Biotech's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech EV-to-Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Kane Biotech's EV-to-Revenue falls into.
Kane Biotech's current Enterprise Value is $5.53 Mil.
Kane Biotech's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kane Biotech (KNBIF) has a EV-to-Revenue of 131.67 as of Aug. 29, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Kane Biotech and its competitors. This is 1293% above median its historical median of 9.45. According to the industry distribution chart, Kane Biotech ranks #819 out of 958 companies in the Biotechnology industry, placing it in the top 85.5%.
Is Kane Biotech's EV-to-Revenue too high?
Kane Biotech's current EV-to-Revenue of 131.67 is 1293% above median its 10-year median of 9.45. The Biotechnology industry median EV-to-Revenue is 8.72. Kane Biotech's value of 131.67 is 1410.8% above this industry median. Based on the distribution chart, Kane Biotech ranks #819 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Kane Biotech's EV-to-Revenue compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #819 out of 958 companies for EV-to-Revenue. This places Kane Biotech in the lower half of its industry. The industry median EV-to-Revenue is 8.72. Kane Biotech's value of 131.67 is 1410.8% above this benchmark. While the company's 10-year median is 9.45 vs. the industry median of 8.72, Kane Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Biotechnology company?
The median EV-to-Revenue among Biotechnology companies is 8.72, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kane Biotech's current EV-to-Revenue of 131.67 is 1410.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Kane Biotech and its competitors. For the Biotechnology industry, the median EV-to-Revenue is 8.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kane Biotech's current EV-to-Revenue is 131.67, which is 1293% above median its own 10-year median of 9.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current EV-to-Revenue of 131.67. The current EV-to-Revenue is 131.67, which is 1293% above median its 10-year median of 9.45 and 1410.8% above the Biotechnology industry median of 8.72. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current EV-to-Revenue is 131.67 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 
